Is Found Weight Loss Legit? What the Data Shows

Found Weight Loss is a real, licensed telehealth company that pairs anti-obesity medications with behavioral coaching delivered through an app. It is not a scam, but whether it is “legit” in the deeper sense depends on how you define the word. The clinical model Found uses, combining remote prescribing of weight-loss drugs with digital health coaching, has genuine peer-reviewed evidence behind it. The trickier questions involve how much of that evidence applies to Found specifically, what happens after you stop treatment, and whether the cost is justified by results you could get elsewhere.

What Found Actually Does

Found operates on a telehealth model where you fill out a health questionnaire, get matched with a clinician (typically a doctor or nurse practitioner), and receive a prescription for one or more weight-loss medications shipped to your door. You also get access to a coaching program through the app. The medications range from older drugs like metformin and bupropion-naltrexone to the newer GLP-1 receptor agonists like semaglutide and liraglutide, depending on your insurance, budget, and clinical profile.

This structure mirrors the telehealth weight-management model studied in several clinical trials. In that model, participants typically connect with a physician monthly and a registered dietitian weekly via video, while tracking data through connected devices.

Does the Telehealth Weight Loss Model Work?

The short answer is yes, but with context. In a controlled trial comparing video-conference-based health coaching to in-person and self-guided groups, participants in the video group lost roughly 8 kg (about 18 pounds) over the study period, compared to around 3 kg in the in-person and control groups.¹ That is a striking difference, though it is worth noting this was a relatively small study and participants knew they were being observed, which tends to boost results.

A broader umbrella review of systematic reviews found that eHealth interventions for weight loss generally outperform doing nothing, with an average advantage of roughly 4 kg, but perform about the same as face-to-face care.² In other words, telehealth is not magic. It works roughly as well as seeing a weight-loss provider in person. That is actually good news for anyone who finds in-person visits inconvenient or inaccessible, but it tempers the idea that Found’s app-based approach offers some unique advantage over traditional care.

A separate trial using the same curriculum that informed Found’s program found that the group receiving weekly telehealth coaching was significantly more adherent to their monitoring devices than the self-guided group, and lost weight at a faster weekly rate.³ The coaching component, not just the medication, appears to matter.

The GLP-1 Medication Question

Much of Found’s current appeal is tied to the explosion of interest in GLP-1 receptor agonist medications, particularly semaglutide (the active ingredient in Wegovy and Ozempic). These drugs genuinely produce substantial weight loss in most people who take them, and the evidence holds up even in real-world telehealth settings outside of carefully controlled clinical trials.

A large retrospective study of 655 patients prescribed semaglutide through a telehealth provider found a mean body weight reduction of about 17%.⁴ The researchers noted that this matches what was seen in the original clinical trials, which is encouraging. A separate study of GLP-1 prescribing through direct-to-consumer telemedicine found that after about 50 days, roughly 86% of patients had lost more than 2 kg, with an average loss of nearly 5 kg.⁵ That is a shorter timeframe, so the numbers are smaller, but the trajectory is consistent with what the larger studies show over longer periods.

If Found prescribes you semaglutide or a similar GLP-1 drug, the medication itself has strong evidence behind it. The platform is, in that case, essentially a delivery mechanism for a well-studied drug. That is not a criticism; getting people connected with effective medications more conveniently is a legitimate service. But it means Found’s results are largely downstream of the medication’s efficacy, not proprietary to Found’s specific approach.

Not Everyone Gets a GLP-1

Found prescribes a range of medications, and not everyone who signs up ends up on semaglutide or tirzepatide. Some people receive metformin, bupropion-naltrexone, or other combinations depending on their clinical picture, insurance, and what they can afford out of pocket. These medications work, but they produce more modest weight loss than the newer GLP-1 drugs.

A network meta-analysis of weight-lowering agents found that naltrexone-bupropion reduced body weight by about 5.6 kg on average, GLP-1 receptor agonists by about 4.7 kg, and metformin by about 1.9 kg.⁶ Those are averages from trials of varying length, and results for any individual will depend heavily on dose, adherence, and lifestyle changes. But the gap between GLP-1 drugs and older options is real, and if cost or insurance barriers push you toward metformin rather than semaglutide, your expected results will be lower.

A twelve-month analysis of real-world data from a telehealth obesity-treatment provider using multiple anti-obesity medications found that side effects were consistent with the classes of drugs prescribed and declined over time.⁷ That suggests the safety profile in the telehealth setting tracks what you would expect from the drugs themselves, which is reassuring.

Why the Coaching Piece Matters More Than You Might Think

A common skepticism about services like Found is that the app-based coaching is just window dressing around a medication prescription. The data suggests otherwise. In a study of a digital weight-loss service that paired semaglutide with lifestyle coaching, participants who were classified as “engaged” with the coaching program lost about 21.5% of their body weight at 11 months, compared to 17% among those who were not engaged, a gap of about 4.5 percentage points.⁸ Both groups were on the same medications. The difference came from engagement with the behavioral component.

Research in older adults using a digital health app found the same pattern: more conversations with coaches, more frequent weigh-ins, and earlier engagement with program content all correlated with greater weight loss.⁹ This matters for anyone evaluating Found, because the medication alone will do a lot of the heavy lifting, but your results will likely be better if you actually use the coaching features rather than treating the app as a pill dispenser.

A UK-based retrospective study of a digital weight-loss service supplementing semaglutide with continuous lifestyle coaching echoed this, noting that the combination achieved higher weight loss than semaglutide alone in prior real-world studies, supporting the recommendation by global health institutions that medication should be used as an adjunct to lifestyle therapy, not a replacement for it.¹⁰

Phenotype-Guided Prescribing and Personalization

Found markets itself as offering personalized treatment, and there is an emerging evidence base for tailoring anti-obesity medications to a person’s specific eating patterns and metabolic profile. A pragmatic clinic trial found that patients whose medications were selected based on their obesity phenotype (for instance, whether they struggled more with constant hunger, emotional eating, or slow metabolism) lost nearly 16% of their body weight at 12 months, compared to 9% in a group that received standard, non-personalized prescribing.¹¹ About 79% of the phenotype-guided group lost more than 10% of their body weight, compared to 34% in the standard group.

A framework review published in 2025 affirmed that matching anti-obesity treatment to both phenotype and complication burden improves personalization and supports better clinical decision-making.¹² Whether Found’s intake questionnaire and clinician assessment actually implement phenotype-guided prescribing with the rigor used in clinical trials is unclear. But the idea that one medication does not fit all and that a thoughtful matching process helps is well supported.

Side Effects You Should Expect

Gastrointestinal side effects are the most common complaint across nearly every anti-obesity medication class, and they tend to be front-loaded during the dose-escalation period. If Found prescribes you a GLP-1 drug, you should be prepared for some stomach trouble, particularly early on.

In the landmark STEP 1 trial of semaglutide, about 74% of people on the drug reported gastrointestinal symptoms, compared to 48% on placebo. Nausea hit roughly 44%, diarrhea 32%, vomiting 25%, and constipation 23%. Most of these were mild to moderate and resolved on their own. Serious gastrointestinal events were rare: gallstones in about 2%, pancreatitis in under 1%. Only about 4.5% of participants stopped semaglutide because of GI side effects.¹³

A network meta-analysis comparing different GLP-1 drugs found that all of them significantly increased the risk of nausea, with some variation. Semaglutide and tirzepatide were also linked to increased vomiting and constipation risk.¹⁴ For the older medications, the side-effect profiles are different: phentermine can cause dry mouth and mild abdominal pain, while orlistat is associated with oily stools and fecal urgency in 15 to 30% of users.¹³

Less commonly discussed but worth knowing: GLP-1 drugs slow gastric emptying, which can increase aspiration risk during anesthesia and complicate bowel preparation for colonoscopies.¹⁵ If you have a surgery or procedure scheduled, make sure every member of your medical team knows you are on one of these medications.

The Weight Regain Problem

This is arguably the most important piece of the Found equation, and one the company’s marketing is less eager to emphasize. The evidence on what happens after you stop GLP-1 medications is now quite clear, and it is sobering.

A systematic review and meta-regression found that after stopping GLP-1 receptor agonists, weight regain follows a predictable curve. At one year off the medication, people had regained about 60% of the weight they originally lost. The regain trajectory appeared to plateau eventually at about 75% of the original weight loss.¹⁶ These patterns were broadly similar regardless of whether the drug was liraglutide, semaglutide, or tirzepatide.

A separate meta-analysis from The BMJ estimated that the monthly rate of weight regain after stopping newer incretin-based drugs was about 0.8 kg (roughly 1.8 pounds) per month.¹⁷ For any weight management medication, the average was about 0.4 kg per month.

What this means practically: for most people, these medications work like blood pressure drugs or statins. They manage a chronic condition while you take them. If Found helps you lose 15% of your body weight on semaglutide, expect to keep only a fraction of that loss if you stop the medication. That does not make the treatment illegitimate, but it does mean the cost is not a one-time investment. You are likely signing up for ongoing treatment, and your budget calculations should reflect that.

Compounded Medications and Quality Concerns

Some telehealth platforms, including Found at various points, have offered compounded versions of semaglutide or tirzepatide. These are made by compounding pharmacies rather than the original manufacturers and typically cost less. There is a real quality and safety gap here that you should understand.

A pharmacovigilance study using the FDA’s adverse event reporting system found that compounded GLP-1 products had dramatically higher rates of preparation errors, prescribing errors, contamination, and compounding or manufacturing issues compared to brand-name versions.¹⁸ The odds ratios for these problems were striking: preparation errors were roughly 49 times more likely to be reported with compounded products, and contamination about 19 times more likely.

Some companies selling compounded GLP-1 products have been found to reference FDA approval in their marketing, which is misleading since compounded versions are by definition not FDA-approved products. If Found or any other platform offers you a compounded GLP-1 medication, ask specifically whether it is the FDA-approved branded product or a compounded version, and factor the safety data into your decision. The lower price comes with a tradeoff in quality control.

Lean Mass Loss and Body Composition

A concern that has gotten increasing attention is that rapid weight loss from GLP-1 drugs leads to muscle loss alongside fat loss. The worry is real but commonly overstated. Analyses of tirzepatide trials found that roughly three-quarters of the weight lost was fat mass and one-quarter was lean mass, proportions that closely resemble what happens with diet-induced weight loss of similar magnitude.¹⁹ The same review noted that observational data do not suggest GLP-1 drugs accelerate muscle wasting beyond what any comparable weight loss would cause.

That said, losing any lean mass is undesirable, particularly for older adults. Resistance training during weight loss, regardless of whether it is medication-assisted, is the best-established countermeasure. If Found’s coaching program encourages strength training alongside the medication, that is a meaningful feature. If it does not, it is a gap worth filling on your own.

Quality of Life Beyond the Scale

Weight loss through a structured online program appears to carry quality-of-life improvements that go beyond the number on the scale. A study of a corporately sponsored online weight-loss program found that increasing weight loss combined with increased physical activity produced the greatest improvements across multiple dimensions. About 64% of participants reported improved energy, 63% improved mood, 65% improved self-confidence, and 68% reported better digestion. Sleep and musculoskeletal pain improved too, though in smaller proportions.²⁰ These improvements were dose-dependent in both directions: more weight loss and more activity each independently predicted better outcomes, and the combination was additive.

Who Might Not Be Well Served

Telehealth weight-loss platforms like Found work best for people who have reliable internet access, a smartphone, comfort with app-based communication, and the financial means to sustain a monthly subscription plus medication costs. That leaves out a substantial number of people who could benefit from obesity treatment.

A systematic review of digital health equity in obesity interventions found that the vast majority of studies simply are not addressing equity concerns. Across 27 studies evaluated, 82% of the digital health equity criteria assessed were marked as “not addressed.”²¹ While this review focused on adolescents, the gap it describes applies broadly. If you lack consistent broadband access, cannot afford the out-of-pocket medication costs, or are uncomfortable navigating a digital platform, services like Found are essentially inaccessible regardless of their clinical efficacy.

People with complex medical histories, including those on multiple medications, those with eating disorders, or those with conditions that complicate medication choices, may also find that a brief telehealth intake does not adequately substitute for the kind of thorough assessment an in-person obesity medicine specialist can provide. The convenience of the model works best for people with straightforward clinical profiles and the resources to participate fully.